{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:18:34Z","timestamp":1780586314972,"version":"3.54.1"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:p>Background: Neuromuscular disease (NMD) research is experiencing tremendous growth as a result of progress in diagnostics and therapeutics yet there continues to be a significant clinical data shortage for these rare diseases. To maximize the development and impact of new therapies, the Muscular Dystrophy Association (MDA) created the neuroMuscular ObserVational Research Data Hub (MOVR) as an observational research study that collects disease-specific measures from individuals living with NMDs in the United States. Objective: This manuscript provides a description of MOVR, participants enrolled in MOVR, and longitudinal data availability. Methods: MOVR collects longitudinal data from individuals diagnosed with ALS, BMD, DMD, FSHD, LGMD, Pompe disease, or SMA, and who are seen for care at a participating MDA Care Center. Data are entered from medical records into standardized electronic case report forms (eCRFs). These eCRFs capture participants\u2019 demographics, diagnostic journeys, clinical visits, and discontinuation from the study. Results: From January 2019 to May 2022, MOVR collected data from 50 participating care centers and 1,957 participants. Data from 1,923 participants who participated in MDA\u2019s pilot registry were migrated into MOVR, creating a total of 3,880 participants in MOVR. Initial analysis of aggregated data demonstrated that 91% of eCRFs were complete. Forty-three percent of participants had 3 or more encounters and 50% of all encounters were 5 months or less from the previous encounter. Discussion: As a centralized data hub for multiple NMDs, MOVR serves as a platform that can be used to inform disease understanding, guide clinical trial design, and accelerate drug development for NMDs.<\/jats:p>","DOI":"10.3233\/jnd-221551","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T12:28:50Z","timestamp":1678451330000},"page":"365-380","source":"Crossref","is-referenced-by-count":6,"title":["The Muscular Dystrophy Association\u2019s neuroMuscular ObserVational Research Data Hub (MOVR): Design, Methods, and Initial Observations"],"prefix":"10.1177","volume":"10","author":[{"given":"Elisabeth A","family":"Kilroy","sequence":"first","affiliation":[{"name":"Muscular Dystrophy Association, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Burris","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edritz","family":"Javelosa","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Waits","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lek","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayne","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Kinevant Sciences, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Opgenorth","sequence":"additional","affiliation":[{"name":"Axogen, Alachua, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Hesterlee","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JND-221551_ref1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pmr.2012.06.011","article-title":"Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases","volume":"23","author":"McDonald","year":"2012","journal-title":"Phys Med Rehabil Clin N Am.495-563"},{"key":"10.3233\/JND-221551_ref2","doi-asserted-by":"crossref","first-page":"12ii","DOI":"10.1136\/jnnp.73.suppl_2.ii12","article-title":"Genetic neuromuscular disease","volume":"73","author":"Reilly","year":"2002","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.3233\/JND-221551_ref3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1474-4422(20)30027-2","article-title":"Leading the way for neuromuscular disorders since 195","volume":"19","author":"The Lancet Neurology","year":"2020","journal-title":"The Lancet Neurology"},{"key":"10.3233\/JND-221551_ref4","doi-asserted-by":"crossref","first-page":"9589","DOI":"10.3390\/ijms21249589","article-title":"Current genetic survey and potential gene-targeting therapeutics for neuromuscular diseases","volume":"21","author":"Chiu","year":"2020","journal-title":"IJMS"},{"key":"10.3233\/JND-221551_ref6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-021-01333-6","volume":"27","author":"Gene therapy needs a long-term approach","year":"2021","journal-title":"Nat Med"},{"key":"10.3233\/JND-221551_ref7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13023-020-01519-0","article-title":"Registries for orphan drugs: Generating evidence or marketing tools","volume":"15","author":"Hollak","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.3233\/JND-221551_ref10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41436-018-0086-5","article-title":"MOVR\u2014NeuroMuscular ObserVational Research, a unified data hub for neuromuscular diseases","volume":"21","author":"Howell","year":"2019","journal-title":"Genetics in Medicine"},{"key":"10.3233\/JND-221551_ref16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with NumPy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"key":"10.3233\/JND-221551_ref19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: A 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Computing in Science & Engineering"},{"key":"10.3233\/JND-221551_ref20","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.21105\/joss.03021","article-title":"seaborn: Statistical data visualization","volume":"6","author":"Waskom","year":"2021","journal-title":"JOSS"},{"key":"10.3233\/JND-221551_ref21","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41436-020-0840-3","article-title":"Sequential targeted exome sequencing of patients affected by unexplained limb-girdle weakness","volume":"22","author":"T\u00f6pf","year":"2020","journal-title":"Genetics in Medicine"},{"key":"10.3233\/JND-221551_ref22","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/acn3.649","article-title":"Genetic landscape and novel disease mechanisms from a large LGMD cohort of patients","volume":"5","author":"Nallamilli","year":"2018","journal-title":"Ann Clin Transl Neuro"},{"key":"10.3233\/JND-221551_ref23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jpeds.2009.02.007","article-title":"Delayed diagnosis in duchenne muscular dystrophy: Data from the muscular dystrophy surveillance, tracking, and research network (MD STARnet)","volume":"155","author":"Ciafaloni","year":"2009","journal-title":"J Pediatr"},{"key":"10.3233\/JND-221551_ref25","first-page":"1","article-title":"Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016","volume":"0","author":"Mehta","year":"2021","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.3233\/JND-221551_ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: Design, methodology, and early findings from the Pompe Registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.3233\/JND-221551_ref28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.23949","article-title":"Risk of functional impairment in Facioscapulohumeral muscular dystrophy","volume":"49","author":"Statland","year":"2014","journal-title":"Muscle & Nerve"},{"key":"10.3233\/JND-221551_ref29","first-page":"118","article-title":"Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature","volume":"41","author":"Chi\u00f2","year":"2013","journal-title":"NED"},{"key":"10.3233\/JND-221551_ref30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.nmd.2010.05.010","article-title":"Clinical and genetic characterization of manifesting carriers of DMD mutations","volume":"20","author":"Soltanzadeh","year":"2010","journal-title":"Neuromuscular Disorders"},{"key":"10.3233\/JND-221551_ref35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-reported outcome (PRO) data from clinical trials: A systematic review and critical analysis","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual Life Outcomes"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-221551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:52:23Z","timestamp":1777506743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-221551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":19,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jnd-221551","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}